A phase II, double blind, placebo-controlled, randomized evaluation of the safety and efficacy of tafenoquine in patients with mild-moderate COVID-19 disease

The safety and efficacy of tafenoquine administered as a 200 mg dose once per day on days 1, 2, 3, and 10 was evaluated over a 28-day period in mild-moderate COVID-19 patients. The primary endpoint was Day 14 clinical recovery from COVID-19 symptoms, defined as cough mild or absent, respiratory rate...

Descripción completa

Detalles Bibliográficos
Autores principales: Dow, G.-S., Smith, B.-L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158239/
https://www.ncbi.nlm.nih.gov/pubmed/35668841
http://dx.doi.org/10.1016/j.nmni.2022.100986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158239/
https://www.ncbi.nlm.nih.gov/pubmed/35668841
http://dx.doi.org/10.1016/j.nmni.2022.100986

Ejemplares similares